Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 2/20 | 0.64 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.64 |
| ▸ | CHRNA7 | P36544 | 1/20 | 0.59 |
| ▸ | TAAR1 | Q96RJ0 | 2/20 | 0.54 |
| ▸ | TRPV6 | Q9H1D0 | 1/20 | 0.50 |
| ▸ | CYP2A6 | P11509 | 1/20 | 0.47 |
| ▸ | CYP19A1 | P11511 | 4/20 | 0.47 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.45 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.45 |
| ▸ | HRH1 | P35367 | 2/20 | 0.45 |
| ▸ | ACHE | P22303 | 1/20 | 0.44 |
| ▸ | HTT | P42858 | 1/20 | 0.43 |
| ▸ | HTR1A | P08908 | 1/20 | 0.42 |
| ▸ | DRD2 | P14416 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL103152 | 0.87 | LMNA (0.68) | LMNATDP1CHRNA7TRPV6CYP2A6 | |
| SCHEMBL6201328 | 0.86 | TAAR1 (0.56) | LMNATDP1CHRNA7TAAR1ACHE | |
| SCHEMBL18906028 | 0.84 | CHRNA7 (0.58) | LMNATDP1CHRNA7TAAR1CYP2A6 | |
| SCHEMBL6204785 | 0.84 | TAAR1 (0.57) | CHRNA7TAAR1TRPV6ALDH1A1SMN1; SMN2 | |
| SCHEMBL4938372 | 0.81 | LMNA (0.68) | LMNATDP1TRPV6CYP19A1ALDH1A1 | |
| SCHEMBL16301357 | 0.81 | LMNA (0.68) | LMNATDP1TRPV6CYP19A1ALDH1A1 | |
| SCHEMBL28824364 | 0.81 | LMNA (0.68) | LMNATDP1TRPV6CYP19A1ALDH1A1 | |
| SCHEMBL6203524 | 0.81 | TAAR1 (0.50) | CHRNA7TAAR1ALDH1A1ACHE | |
| SCHEMBL6203586 | 0.81 | TAAR1 (0.54) | LMNATDP1TAAR1ALDH1A1ACHE | |
| SCHEMBL415399 | 0.80 | TAAR1 (0.65) | TAAR1CYP2A6SMN1; SMN2HRH1ACHE |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1581498-A2 | PYRIDINYL, PYRIMIDINYL AND PYRAZINYL AMIDES AS POTASSIUM CHANNEL OPENERS | Bristol-Myers Squibb Company (US) | 2005-10-05 | — | — | EP | disclosed |
| US-6900210-B2 | Pyridinyl, pyrimidinyl and pyrazinyl amides as potassium channel openers | BRISTOL-MYERS SQUIBB COMPANY (US) | 2005-05-31 | — | — | US | disclosed |
| WO-2004047739-A2 | PYRIDINYL, PYRIMIDINYL AND PYRAZINYL AMIDES AS POTASSIUM CHANNEL OPENERS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2004-06-10 | — | — | WO | disclosed |
| US-20040102449-A1 | Pyridinyl, pyrimidinyl and pyrazinyl amides as potassium channel openers | BRISTOL-MYERS SQUIBB COMPANY | 2004-05-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040102449-A1 | Pyridinyl, pyrimidinyl and pyrazinyl amides as potassium channel openers | KCNQ5, KCNQ2, KCNQ3 | LMNA 1434/4885TDP1 4075/4885CHRNA7 124/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.